Market cap
$1,005 Mln
Revenue (TTM)
$357 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 23.74 | 20.14 | 3.18 | 28.72 | 35.55 |
| EBIT | 89.52 | -1,127.05 | -89.87 | 21.37 | 2.27 |
| Net Profit | 85.81 | -145.54 | -105.10 | 21.23 | 2.64 |
| EPS | 86.05 | -144.27 | -82.85 | 21.78 | 6.05 |
| Book Value | -- | -- | 6.35 | 2.02 | -4.26 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -9.33 | -24.15 | -5.27 | -8.55 | 6.67 |
| Net Margin
| -- | -- | -5.43 | -- | -- |
| Return on equity
| -5.15 | -7.91 | -4.13 | -5.21 | 4.31 |
| Return on Capital
| -4.94 | -7.68 | -- | -4.88 | 4.11 |
| Return on Assets
| -4.47 | -7.02 | -3.20 | -4.35 | 3.71 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.08 | 0.06 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
-4.88
|
4.11
|
-14.03
|
-16.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-4.13
Lower than Peers by 9.10
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-4.13
|
-5.21
|
4.31
|
-14.54
|
-16.56
|
|
Peer Median
|
4.98
|
--
|
--
|
--
|
--
|
ROA
-3.20
Lower than Peers by 5.67
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-3.20
|
-4.35
|
3.71
|
-12.76
|
-14.76
|
|
Peer Median
|
2.47
|
--
|
--
|
--
|
--
|
EBIT Margin
-5.27
Lower than Peers by 13.76
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-5.27
|
-8.55
|
6.67
|
-26.10
|
-50.27
|
|
Peer Median
|
8.49
|
--
|
--
|
--
|
--
|
Net Margin
-5.43
Lower than Peers by 10.19
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-5.43
|
-7.02
|
5.49
|
-26.15
|
-48.99
|
|
Peer Median
|
4.75
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
3.18
Lower than Peers by 5.39
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
3.18
|
0.04
|
0.51
|
0.60
|
0.46
|
|
Peer Median
|
8.57
|
--
|
--
|
--
|
--
|
EBIT Growth
-89.87
Lower than Peers by 100.26
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-89.87
|
-232.91
|
138.60
|
16.74
|
-72.17
|
|
Peer Median
|
10.38
|
--
|
--
|
--
|
--
|
Net Profit Growth
-105.10
Lower than Peers by 118.71
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-105.10
|
-232.41
|
131.75
|
14.41
|
-114.55
|
|
Peer Median
|
13.61
|
--
|
--
|
--
|
--
|
EPS Growth
-82.85
Lower than Peers by 103.93
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-82.85
|
-2.36
|
1.29
|
0.17
|
-1.06
|
|
Peer Median
|
21.08
|
--
|
--
|
--
|
--
|
Book Value Growth
0.32
Lower than Peers by 6.75
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
0.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
7.07
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
Lower than Peers by 0.38
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
0.02
|
0.08
|
0.06
|
0.04
|
0.03
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.04
Higher than Peers by 3.21
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
6.04
|
5.26
|
7.29
|
6.20
|
8.09
|
|
Peer Median
|
2.82
|
--
|
--
|
--
|
--
|
Quick Ratio
5.85
Higher than Peers by 3.81
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
5.85
|
5.11
|
7.13
|
6.04
|
7.98
|
|
Peer Median
|
2.04
|
--
|
--
|
--
|
--
|
Interest Coverage
-50.21
Lower than Peers by 55.23
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
-50.21
|
-342.19
|
38.37
|
-5,214.00
|
-4,052.18
|
|
Peer Median
|
5.02
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
13.53
Lower than Peers by 2.93
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
13.53
|
12.60
|
15.42
|
17.43
|
17.13
|
|
Peer Median
|
16.46
|
--
|
--
|
--
|
--
|
Asset Turnover
0.59
Higher than Peers by 0.09
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
0.59
|
0.62
|
0.67
|
0.49
|
0.30
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
50.19
|
49.23
|
51.33
|
54.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
47.28
|
48.77
|
48.40
|
34.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
65.85
|
52.08
|
60.90
|
41.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
31.62
|
45.92
|
38.84
|
47.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
-47.23
|
44.11
|
-10.19
|
-9.26
|
|
Peer Median
|
46.09
|
--
|
--
|
--
|
--
|
Price / Book Value
2.17
Lower than Peers by 1.62
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
2.17
|
2.42
|
1.77
|
1.50
|
1.56
|
|
Peer Median
|
3.79
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
42.95
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
42.95
|
77.45
|
14.11
|
-7.95
|
-6.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1,005
Higher than Peers by 465
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
|
1,005
|
--
|
--
|
--
|
--
|
|
Peer Median
|
540
|
--
|
--
|
--
|
--
|